Last reviewed · How we verify
NCT04590300: MetaCOGNITION
Impact of Cognitive & Metacognitive Performance on Knowledge Learning When Conducting Therapeutic Education Programs
NA trial testing QUESTIONNAIRES in Schizophrenia in 108 participants. Completed in 31 December 2022.
1 September 2022
Quick facts
| Lead sponsor | Centre Hospitalier Charles Perrens, Bordeaux |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 108 |
| Start date | 6 October 2020 |
| Primary completion | 1 September 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- QUESTIONNAIRES
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Bipolar Disorder — all drugs for Bipolar Disorder →
Sponsor
Centre Hospitalier Charles Perrens, Bordeaux
Who can join
18 and older, any sex, with Schizophrenia or Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
People with schizophrenia and bipolar disorder display alterations in cognition and metacognition. These alterations may have an impact on learning during therapeutic education programs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04590300
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of QUESTIONNAIRES
Trials testing the same drug.
- NCT06478849 — Adherence and Understanding of a Therapeutic Education Program for Patients With Central Venous Access (EDUVVC) · recruiting
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Centre Hospitalier Charles Perrens, Bordeaux trials
Trials by the same sponsor.
- NCT07309159 — Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life · Phase 1, PHASE2 · not yet recruiting
- NCT07008183 — Perinatal Thymic DYsregulation: Characterization of Perinatal Mood Episodes · NA · recruiting
- NCT06738784 — Evaluation of the Efficiency of the PRPP (Perceive, Recall, Plan and Perform) Task Analysis System on Support and Orient · NA · recruiting
- NCT05381883 — Mental Health of Professionals of the Silver Economy of New Aquitaine : Online Survey of Accommodation Establishments fo · NA · not yet recruiting
- NCT06476873 — Substance Use Disorder in Chemsex Practice · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04590300 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Charles Perrens, Bordeaux
- Last refreshed: 18 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04590300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing